FIT, based in the Oxford Science Park and utilising new-generation technologies developed from the collaboration between ISIS and FIT's existing world-leading autoinjector design team, have developed and launched a new range of needle-safe autoinjectors required for the imminent explosion in the demand for such devices, especially for viscous drugs.